

L2 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2003 ACS

RN 10121-91-2 REGISTRY

CN 1-Naphthalenesulfonamide, N-(5-aminopentyl)-5-(dimethylamino)- (8CI, 9CI) (CA INDEX NAME)

OTHER NAMES:

CN Dansylcadaverine

CN Monodansylcadaverine

CN N-(5-Aminopentyl)-5-dimethylamino-1-naphthalenesulfonamide

FS 3D CONCORD

DR 99473-69-5

MF C17 H25 N3 O2 S

LC STN Files: ADISNEWS, AGRICOLA, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CHEMCATS, CHEMLIST, CSCHEM, DDFU, DRUGU, EMBASE, MEDLINE, NIOSHTIC, TOXCENTER, USPATFULL, VETU (*File contains numerically searchable property data)
Other Sources: EINECS**

(**Enter CHEMLIST File for up-to-date regulatory information)

$$O = S - NH - (CH2)5 - NH2$$

$$NMe2$$

=>

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

263 REFERENCES IN FILE CA (1957 TO DATE)

12 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

263 REFERENCES IN FILE CAPLUS (1957 TO DATE)

•



```
ANSWER 1 OF 1 - REGISTRY COPYRIGHT 2002 ACS
     462-94-2 REGISTRY
RN
CN
     1,5-Pentanediamine (8CI, 9CI) (CA INDEX NAME)
OTHER NAMES:
     .alpha.,.omega.-Pentanediamine
CN
CN
     1,5-Amylene diamine
CN
     1,5-Diamino-n-pentane
CN
     1,5-Diaminopentane
CN
     1,5-Pentamethylenediamine
CN
     Cadaverine
CN
     Pentamethylenediamine
FS
     3D CONCORD
MF
     C5 H14 N2
CI
     COM
LC
     STN Files:
                 AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS,
       BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CHEMCATS,
       CHEMINFORMRX, CHEMLIST, CSCHEM, DDFU, DETHERM*, DRUGU, EMBASE, GMELIN*,
       HODOC*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, NAPRALERT,
       NIOSHTIC, PIRA, PROMT, RTECS*, SPECINFO, SYNTHLINE, TOXCENTER, USPAT2,
       USPATFULL
```

(*File contains numerically searchable property data)
Other Sources: EINECS**

(**Enter CHEMLIST File for up-to-date regulatory information)

 $H_2N-(CH_2)_5-NH_2$

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2949 REFERENCES IN FILE CA (1962 TO DATE)
78 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
2958 REFERENCES IN FILE CAPLUS (1962 TO DATE)
17 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

```
L3
     ANSWER 1 OF 1 REGISTRY COPYRIGHT 2002 ACS
RN
     51-85-4 REGISTRY
     Ethanamine, 2,2'-dithiobis- (9CI) (CA INDEX NAME)
CN
OTHER CA INDEX NAMES:
     Ethylamine, 2,2'-dithiobis- (8CI)
OTHER NAMES:
CN
     .beta.,.beta.'-Diaminodiethyl disulfide
     .beta.-Mercaptoethylamine disulfide
CN
     1,6-Diamino-3,4-dithiahexane
CN
CN
     2,2'-Dithiobis[ethanamine]
CN
     2,2'-Dithiobis[ethylamine]
CN
     2,2'-Dithiodiethylamine
CN
     2-Aminoethane disulfide
CN
     2-Aminoethyl disulfide
CN
     Bis(.beta.-aminoethyl) disulfide
CN
     Bis(2-aminoethyl) disulfide
CN
     Cystamine
CN
     Cysteinamine disulfide
CN
     Cystineamine
CN
     Decarboxycystine
CN
     L 1591
CN
     Mercamine disulfide
CN
     Merkamine disulfide
FS
     3D CONCORD
MF
     C4 H12 N2 S2
CI
     COM
LC
                  ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS,
     STN Files:
       BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CEN,
       CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, DDFU, DRUGU, EMBASE, IFICDB,
       IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, NAPRALERT, NIOSHTIC, PIRA, PROMT,
       RTECS*, TOXCENTER, USPATFULL
         (*File contains numerically searchable property data)
     Other Sources:
                      EINECS**
         (**Enter CHEMLIST File for up-to-date regulatory information)
H_2N-CH_2-CH_2-S-S-CH_2-CH_2
```

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1501 REFERENCES IN FILE CA (1962 TO DATE)

61 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

1504 REFERENCES IN FILE CAPLUS (1962 TO DATE)

25 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

3

```
ANSWER 1 OF 1 REGISTRY COPYRIGHT 2002 ACS
L4
RN
     110-60-1 REGISTRY
     1,4-Butanediamine (8CI, 9CI) (CA INDEX NAME)
CN
OTHER CA INDEX NAMES:
     Tetramethylenediamine (7CI)
OTHER NAMES:
     .alpha.,.omega.-Butanediamine
CN
CN
     1,4-Butylenediamine
CN
     1,4-Diamino-n-butane
CN
     1,4-Diaminobutane
CN
     1,4-Tetramethylenediamine
CN
     Putrescin
CN
     Putrescine
FS
     3D CONCORD
MF
     C4 H12 N2
CI
     COM
LC
     STN Files: AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS,
       BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CEN,
       CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, DDFU, DETHERM*, DRUGNL,
      DRUGPAT, DRUGU, DRUGUPDATES, EMBASE, GMELIN*, HODOC*, IFICDB, IFIPAT,
       IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PIRA, PROMT,
       RTECS*, SPECINFO, SYNTHLINE, TOXCENTER, USPAT2, USPATFULL
         (*File contains numerically searchable property data)
     Other Sources: EINECS**, NDSL**, TSCA**
         (**Enter CHEMLIST File for up-to-date regulatory information)
```

 $H_2N-(CH_2)_4-NH_2$

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10206 REFERENCES IN FILE CA (1962 TO DATE)
409 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
10224 REFERENCES IN FILE CAPLUS (1962 TO DATE)
1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

```
L8
     ANSWER 1 OF 1 REGISTRY COPYRIGHT 2002 ACS
RN
     56-12-2 REGISTRY
     Butanoic acid, 4-amino- (9CI) (CA INDEX NAME)
CN
OTHER CA INDEX NAMES:
     Butyric acid, 4-amino- (7CI, 8CI)
OTHER NAMES:
CN
     .gamma.-Aminobutanoic acid
CN
     .gamma.-Aminobutyric acid
CN
     .omega.-Aminobutyric acid
CN
     3-Carboxypropylamine
CN
     4-Aminobutanoic acid
CN
     4-Aminobutyric acid
CN
     Aminalon
CN
     GABA
     Gaballon
CN
CN
     Gamarex
CN
     Gammalon
CN
     Gammalone
CN
     Gammar
CN
     Gammasol
CN
     Mielogen
CN
     Mielomade
CN
     Piperidic acid
CN
     Piperidinic acid
     3D CONCORD
FS
DR
     3131-86-0
     C4 H9 N O2
MF
CI
     COM
LC
                  ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS,
     STN Files:
       BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CEN,
       CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, DDFU, DETHERM*, DRUGU,
       EMBASE, GMELIN*, HODOC*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*,
       MSDS-OHS, NAPRALERT, NIOSHTIC, PROMT, RTECS*, SPECINFO, SYNTHLINE,
       TOXCENTER, ULIDAT, USAN, USPAT2, USPATFULL, VETU
         (*File contains numerically searchable property data)
     Other Sources: DSL**, EINECS**, TSCA**
         (**Enter CHEMLIST File for up-to-date regulatory information)
```

 $H_2N^{\frac{1}{2}}$ (CH₂)₃ - CO₂H

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

23850 REFERENCES IN FILE CA (1962 TO DATE)
419 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
23879 REFERENCES IN FILE CAPLUS (1962 TO DATE)
1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=>

```
=> D L2 1-18 BIB, KWIC
     ANSWER 1 OF 18 USPATFULL
1.2
       2003:17890 USPATFULL
ΑN
       Hemoglobin-haptoglobin complexes
TТ
       Adamson, J. Gordon, Georgetown, CANADA
TN
       Wodzinska, Jolanta M., Brampton, CANADA
       Moore, M.S. Celine, Georgetown, CANADA
PΑ
       Hemosol, Inc. (non-U.S. corporation)
       US 2003013642
                          A1
                               20030116
PΤ
       US 2002-231062
                          A1
                               20020830 (10)
AΤ
       Continuation of Ser. No. US 1999-302351, filed on 30 Apr 1999, GRANTED,
RLI
       Pat. No. US 6479637
PRAI
       CA 1998-2236344
                           19980430
DT
      Utility
FS
      APPLICATION
      NIXON & VANDERHYE P.C., 8th Floor, 1100 North Glebe Road, Arlington, VA,
LREP
       22201-4714
      Number of Claims: 30
CLMN
ECL
      Exemplary Claim: 1
DRWN
       12 Drawing Page(s)
LN.CNT 1066
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
      512-69-6, Raffinose 10121-91-2, Monodansyl cadaverine
TT
      20166-34-1, reactions
                             63368-54-7, 5-Iodoacetamido fluorescein
      65989-10-8
        (Hb-haptoglobin complexes for hepatic drug delivery)
     ANSWER 2 OF 18 USPATFULL
L2
AN
       2002:156777 USPATFULL
TT
       Method for determining the suitability of a transparent moulded polymer
       article for colouring without defects and resulting article
       Massey, Gilles, Saint-Maur, FRANCE
TN
       Dauguet, Jean-Claude, Marolles en Brie, FRANCE
       ESSILOR INTERNATINAL COMPAGNIE GENERALE d'OPTIQUE, Charenton Cedex,
PΑ
       FRANCE (non-U.S. corporation)
PΙ
       US 2002081375
                          A1
                               20020627
                               20011005 (9)
AΤ
       US 2001-972396
                          A1
       Continuation of Ser. No. WO 2000-FR842, filed on 5 Apr 2000, UNKNOWN
RLT
       FR 1999-4268
                           19990406
PRAT
DΤ
      Utility
      APPLICATION
FS
      Mark B. Wilson, FULBRIGHT & JAWORSKI L.L.P., Suite 2400, 600 Congress
LREP
       Avenue, Austin, TX, 78701
CLMN
       Number of Claims: 19
ECL
       Exemplary Claim: 1
DRWN
      No Drawings
LN.CNT 359
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
    10121-91-2, Dansyl cadaverine
        (in detg. flawless colorability of transparent molded object made from
        polymer materials such as ophthalmic lenses)
     ANSWER 3 OF 18 USPATFULL
L2
AN
       2002:297687 USPATFULL
       Hemoglobin-haptoglobin complexes
ΤI
       Adamson, J. Gordon, Georgetown, CANADA
IN
       Wodzinska, Jolanta Maria, Brampton, CANADA
       Moore, M. S. Celine, Georgetown, CANADA
PA
       Hemsol Inc., Ontario, CANADA (non-U.S. corporation)
PΙ
       US 6479637
                          B1
                               20021112
AΙ
       US 1999-302351
                               19990430 (9)
                           19980430
```

PRAI

CA 1998-2236344

```
DT
       Utility
       GRANTED
FS
       Primary Examiner: Reynolds, Deborah J.; Assistant Examiner: Sorbello,
EXNAM
       Nixon & Vanderhye
LREP
       Number of Claims: 68
CLMN
       Exemplary Claim: 1
ECL
       31 Drawing Figure(s); 17 Drawing Page(s)
DRWN
LN.CNT 1425
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
      512-69-6, Raffinose 10121-91-2, Monodansyl cadaverine
      20166-34-1, reactions 63368-54-7, 5-Iodoacetamido fluorescein
      65989-10-8
        (Hb-haptoglobin complexes for hepatic drug delivery)
     ANSWER 4 OF 18 USPATFULL
L<sub>2</sub>
       2002:160844 USPATFULL
AN
ΤI
       Parasitic nematode transglutaminase proteins and uses thereof
       Chandrashekar, Ramaswamy, Fort Collins, CO, United States
TN
       Mehta, Kapil, Houston, TX, United States
       Heska Corporation, Fort Collins, CO, United States (U.S. corporation)
PΔ
       Board of Regents, The University of Texas System, Austin, TX, United
       States (U.S. corporation)
       US 6414115
                               20020702
PΤ
                          B1
       US 1998-6595
                               19980113 (9)
AΙ
       Division of Ser. No. US 1996-781420, filed on 3 Dec 1996
RLI
DТ
       Utility
       GRANTED
FS
EXNAM Primary Examiner: Minnifield, Nita
       Heska Corporation
LREP
       Number of Claims: 14
CLMN
ECL
       Exemplary Claim: 1
       0 Drawing Figure(s); 0 Drawing Page(s)
DRWN
LN.CNT 2894
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
      51-85-4, Cystamine
                           144-48-9, Iodoacetamide 10121-91-2,
TΤ
      Monodansylcadaverine
        (transglutaminase inhibitors effect on nematode larval molting;
        parasitic nematode transglutaminase proteins and nucleic acid mols.,
        and their uses for inhibitor screening and recombinant vaccines)
L2
     ANSWER 5 OF 18 USPATFULL
       2002:102286 USPATFULL
ΑN
       Parasitic nematode transglutaminase, nucleic acid molecules and uses
ΤI
       Chandrashekar, Ramaswamy, Fort Collins, CO, United States
TN
       Heska Corporation, Fort Collins, CO, United States (U.S. corporation)
PA
PI
       US 6383774
                          B1
                               20020507
       US 1997-984919
                               19971204 (8)
AΤ
       Continuation-in-part of Ser. No. US 1997-874102, filed on 12 Jun 1997,
RLT
       now patented, Pat. No. US 6309644 Continuation-in-part of Ser. No. US
       1996-781420, filed on 3 Dec 1996, now patented, Pat. No. US 6248872
DT
       Utility
FS
       GRANTED
EXNAM Primary Examiner: Navarro, Mark
       Heska Corporation
LREP
CLMN
       Number of Claims: 18
ECL
       Exemplary Claim: 1
       0 Drawing Figure(s); 0 Drawing Page(s)
DRWN
LN.CNT 4522
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
                                            110-60-1, Putrescine
                                                                   144-48-9,
      51-85-4, Cystamine
                           77-86-1, TRIS
                      7447-40-7, Potassium chloride (KCl), biological studies
      Iodoacetamide
      7647-14-5, Sodium chloride, biological studies
                                                       7664-41-7, Ammonia,
```

```
transglutaminase/protein disulfide isomerase enzymes of parasitic
        nematodes and their potential use in treatment of infection in cats and
        dogs)
     ANSWER 6 OF 18 USPATFULL
L2
       2002:51017 USPATFULL
AN
       Remedy for CAG repeat expansion diseases
TТ
       Tsuji, Shoji, Niigata, JAPAN
IN
       Niigata University, JAPAN (non-U.S. corporation)
PΑ
                               20020312
                          B1
       US 6355690
PΙ
       US 1999-236002
                               19990122 (9)
ΑI
       JP 1998-27739
                           19980126
PRAI
       Utility
DT
FS
       GRANTED
       Primary Examiner: Geist, Gary; Assistant Examiner: Maier, Leigh C.
EXNAM
       Burns, Doane, Swecker & Mathis, LLP
LREP
       Number of Claims: 3
CLMN
ECL
       Exemplary Claim: 1
       30 Drawing Figure(s); 14 Drawing Page(s)
DRWN
LN.CNT 719
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
      60-23-1, Cysteamine 10121-91-2, Monodansyl cadaverine
IΤ
        (therapeutic agents for CAG repeat expansion disease)
     ANSWER 7 OF 18 USPATFULL
L2
       2001:214853 USPATFULL
ΑN
       Protein modification method
TΤ
       Sato, Haruya, Chiba-ken, Japan
TN
       Yamamoto, Keiji, Chiba-ken, Japan
       Suzuki, Kokichi, Chiba-ken, Japan
       Ikeda, Masahiro, Tokyo, Japan
       Sakagami, Masahiro, Chiba-ken, Japan
       Taniguchi, Makoto, Saitama-ken, Japan
       Drug Delivery System Institute, Ltd., Tokyo, Japan (non-U.S.
PA
       corporation)
                               20011127
PΤ
       US 6322996
                          B1
       WO 9606181 19960229
       US 1995-505250
                               19951129 (8)
AΙ
       WO 1995-JP298
                               19950227
                                         PCT 371 date
                               19951129
                               19951129 PCT 102(e) date
       JP 1994-198187
                           19940823
PRAT
       Utility
תת
FS
       GRANTED
       Primary Examiner: Wortman, Donna C.; Assistant Examiner: Brumback,
EXNAM
       Brenda G.
       Oblon, Spivak, Mclleland, Maier & Neustadt, P.C.
LREP
       Number of Claims: 10
CLMN
       Exemplary Claim: 1
ECL
       9 Drawing Figure(s); 9 Drawing Page(s)
DRWN
LN.CNT 1761
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
   10121-91-2, DANSYLCADAVERINE
                                   25322-68-3
                                                 80146-85-6,
      Transglutaminase
        (modification of protein with amino group donors in presence of
        transglutaminase to improve adaptability)
     ANSWER 8 OF 18 USPATFULL
L2
AN
       2001:190730 USPATFULL
TI
       Parasitic nematode transglutaminase proteins and uses thereof
IN
       Chandrashekar, Ramaswamy, Fort Collins, CO, United States
```

biological studies

studies 10121-91-2, Monodansylcadaverine

7783-20-2, Sulfuric acid diammonium salt, biological

(transglutaminase activity inhibited by; inhibitors to bifunctional

```
Mehta, Kapil, Houston, TX, United States
       Heska Corporation, Fort Collins, CO, United States (U.S. corporation)
PA
       The Board of Regents, The University of Texas System, Austin, TX, United
       States (U.S. corporation)
                               20011030
       US 6309644
                          B1
PΤ
                               19970612 (8)
       US 1997-874102
ΑI
       Continuation-in-part of Ser. No. US 1996-781420, filed on 3 Dec 1996,
RLI
       now patented, Pat. No. US 6248872
       Utility
DT
       GRANTED
FS
      Primary Examiner: Navarro, Mark
EXNAM
      Heska Corporation
LREP
      Number of Claims: 18
CLMN
       Exemplary Claim: 1
ECL
       No Drawings
DRWN
LN.CNT 3195
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
   10121-91-2, Monodansylcadaverine
        (parasitic nematode transglutaminase proteins and uses thereof)
     ANSWER 9 OF 18 USPATFULL
L2
       2001:93638 USPATFULL
AN
       Parasitic nematode transglutaminase, nucleic acid molecules, and uses
TΤ
       thereof
       Chandrashekar, Ramaswamy, Fort Collins, CO, United States
IN
       Heska Corporation, Fort Collins, CO, United States (U.S. corporation)
PA
                          B1
                               20010619
PΙ
       US 6248872
       US 1996-781420
                               19961203 (8)
ΑI
DT
       Utility
FS
       GRANTED
EXNAM Primary Examiner: Minnifield, Niya
LREP
       Heska Corporation
CLMN
       Number of Claims: 10
ECL
       Exemplary Claim: 1
DRWN
       No Drawings
LN.CNT 2445
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
                           144-48-9, Iodoacetamide 10121-91-2,
      51-85-4, Cystamine
IT
      Monodansylcadaverine
        (transglutaminase inhibitors effect on nematode larval molting;
        parasitic nematode transglutaminase proteins and nucleic acid mols.,
        and their uses for inhibitor screening and recombinant vaccines)
     ANSWER 10 OF 18 USPATFULL
L2
       2001:82819 USPATFULL
AN
       Substituted .beta.-amino acid inhibitors of methionine aminopeptidase-2
ΤI
       Craig, Richard A., Racine, WI, United States
TN
       Henkin, Jack, Highland Park, IL, United States
       Kawai, Megumi, Libertyville, IL, United States
       Lynch, Linda M., Pleasant Prairie, WI, United States
       Patel, Jyoti, Libertyville, IL, United States
       Sheppard, George S., Willmette, IL, United States
       Wang, Jieyi, Gurnee, IL, United States
       Abbott Laboratories, Abbott Park, IL, United States (U.S. corporation)
PA
                               20010605
PΙ
       US 6242494
                          В1
                               19990430 (9)
       US 1999-303807
AΙ
       US 1998-83877P
                           19980501 (60)
PRAI
DT
       Utility
FS
       Granted
      Primary Examiner: Aulakh, C. S.
EXNAM
       Donner, B. Gregory, Steele, Gregory W.
LREP
       Number of Claims: 15
CLMN
ECL
       Exemplary Claim: 1
DRWN
       No Drawings
```

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

55-81-2 62-53-3, Benzenamine, reactions 64-04-0, 1-Amino-2phenylethane 79-14-1, reactions 87-62-7, 2,6-Dimethylaniline 89-99-6, 2-Fluorobenzylamine 90-04-0, o-Anisidine 91-21-4, 1,2,3,4-Tetrahydroisoquinoline 93-11-8, 2-Naphthylsulfonyl chloride 94-64-4, 2-Chloro-N-methylbenzylamine 94-70-2, 2-Ethoxyaniline 94-85-9, 2,5-Diethoxyaniline 95-00-1, 2,4-Dichlorobenzylamine 95-03-4, 2-Methoxy-5-chloroaniline 95-51-2, 2-Chloroaniline 95-76-1, 3,4-Dichloroaniline 96-32-2, Methyl bromoacetate 97-50-7 3-(Trifluoromethyl)aniline 99-55-8, 2-Methyl-5-nitroaniline 99-57-0, 2-Amino-4-nitrophenol 99-59-2, 2-Methoxy-5-nitroaniline 100-81-2, 3-Methyl benzylamine 102-56-7, 2,5-Dimethoxyaniline 104-75-6, 2-Ethylhexylamine 104-84-7, 4-Methylbenzylamine 104-86-9, 4-Chlorobenzylamine 104-94-9, p-Anisidine 106-40-1, 4-Bromoaniline 106-47-8, 4-Chloroaniline, reactions 106-49-0, p-Toluidine, reactions 107-45-9, tert-Octylamine 108-09-8, 1,3-Dimethylbutylamine 3-Chloroaniline 108-85-0, Cyclohexyl bromide 108-91-8, Cyclohexylamine, reactions 110-89-4, Piperidine, reactions 111-49-9 111-95-5 118-31-0, 1-Naphthylmethylamine 120-71-8, 2-Methoxy-5-methylaniline 121-60-8, 4-Acetamidobenzenesulfonyl chloride 121-88-0, 2-Amino-5-nitrophenol 123-82-0, 1-Methylhexylamine 139-59-3, 4-Phenoxyaniline 141-91-3, 2,6-Dimethylmorpholine trans-2-Phenylcyclopropylamine 156-41-2, 4-Chloro phenethylamine 349-55-3, 3-Methoxy-5-(trifluoromethyl)aniline 349-65-5 371-40-4, 4-Fluoroaniline 402-49-3, 4-Trifluoromethylbenzyl bromide 403-40-7 404-70-6, 3-Fluorophenethylamine 455-14-1, 4-(Trifluoromethyl)aniline 536-90-3, 3-Methoxyaniline 543-82-8, 1,5-Dimethylhexylamine 554-00-7, 2,4-Dichloroaniline 589-08-2 598-74-3, 1,2-Dimethylpropylamine 608-07-1, 5-Methoxy tryptamine 608-31-1, 2,6-Dichloroaniline 617-89-0, Furfurylamine 621-33-0, 3-Ethoxyaniline 768-94-5, Tricyclo[3.3.1.13,7]decan-1-amine 769-92-6, 4-tert-Butylaniline 822-98-0, 2-Aminonorbornane 924-73-2, Ethyl 1003-03-8, Cyclopentylamine 1113-49-1, 3-amino-propionate .alpha.-Aminoisobutyric acid ethyl ester 1115-59-9, L-Alanine ethylester hydrochloride 1126-09-6, Ethyl isonipecotate 1200-27-7 1477-68-5, 3-O-Methyl dopamine hydrochloride 1484-26-0, 3-Benzyloxyaniline 1535-73-5, 3-(Trifluoromethoxy)aniline 1535-75-7, 2-(Trifluoromethoxy)aniline 1572-10-7, 3-Amino-5-phenyl pyrazole 1583-88-6, 4-Fluoro phenethylamine 1716-60-5 1824-81-3, 2-Amino-6-methylpyridine 1886-26-6 2038-57-5, 1-Amino-3-phenylpropane 2039-67-0, 3-Methoxy phenethylamine 2045-79-6, 2-Methoxy phenethylamine 2217-40-5, 1,2,3,4-Tetrahydro-1-naphthylamine 2393-23-9, 4-Methoxybenzylamine 2403-22-7, n-Butylbenzylamine 2417-72-3, 4-Methoxycarbonylbenzyl bromide 2488-15-5, N-(tert-Butoxycarbonyl)-Lmethionine 2516-34-9, Cyclobutylamine 2524-67-6, 4-Morpholinoaniline 2577-46-0, L-Isoleucine methyl ester 2577-90-4, Phenylalanine methyl 2620-50-0, Piperonylamine 2666-93-5, L-Leucine methyl ester 2688-84-8, 2-Phenoxyaniline 2706-56-1, 2-Pyridineethanamine 2735-04-8, 2,4-Dimethoxyaniline 2740-83-2, 3-(Trifluoromethyl) benzylamine 2764-95-6, 4-Methoxy-2-naphthylamine 2885-01-0, Glycine butyl ester 2906-12-9, 3-Isopropoxypropylamine 3048-01-9, 2-Trifluoromethyl benzylamine 3082-62-0 3218-02-8, Cyclohexanemethanamine 3261-62-9 3300-51-4, 4-3528-58-3, 5-Amino-1-ethylpyrazole (Trifluoromethyl) benzylamine 3586-12-7, 3-Phenoxyaniline 3886-70-2 3906-16-9 3959-07-7, 4-Bromo benzylamine 4070-48-8, L-Valine methyl ester 4152-90-3, 3-Chlorobenzylamine 4333-56-6, Cyclopropyl bromide 4795-29-3, Tetrahydrofurfurylamine 5036-48-6, 1-(3-Aminopropyl)imidazole 5071-96-5, 3-Methoxybenzylamine 5241-66-7, N-(tert-Butoxycarbonyl)-D-5400-88-4 5452-35-7, Cycloheptylamine methionine 5350-93-6 5586-73-2, 3,3-Diphenylpropylamine 5834-17-3, 3-Amino-2methoxydibenzofuran 5840-10-8 5959-36-4, Ethyl 4-amino-butyrate 5993-91-9, 2-(Aminomethyl)benzimidazole dihydrochloride 6299-67-8,

```
6315-89-5, 3,4-Dimethoxyaniline 6331-09-5,
      2,3-Dimethoxyaniline
      D-Alanine ethyl ester hydrochloride 6358-64-1 6375-47-9
                                                                 6376-14-3
                 6485-55-8, cis-2,6-Dimethylmorpholine
                                                        7307-55-3,
      6456-74-2
      Undecylamine 7663-77-6, 1-(3-Aminopropyl)-2-pyrrolidone
                 10272-07-8, 3,5-Dimethoxyaniline 10420-89-0
      10121-91-2
      13074-39-0, Tricyclo[3.3.1.13,7]decan-2-amine 13078-79-0, 3-Chloro
                     13078-80-3, 2-(2-Chlorophenyl)ethylamine
      phenethylamine
      1-Amino-4-phenylbutane 13258-63-4, 4-Pyridineethanamine
      14268-66-7, 3,4-Methylenedioxyaniline 14489-75-9
                                                        14529-00-1, Benzyl
      3-amino-propionate 16452-01-0, 3-Methoxy-4-methylaniline
      17831-01-5, L-Alanine benzyl ester 17950-40-2, Triethyloxonium
      hexafluorophosphate 18807-71-1 18807-73-3 18880-00-7,
      4-tert-Butylbenzyl bromide 18942-49-9, N-(tert-Butoxycarbonyl)-D-
      phenylalanine 20173-24-4, 3-Pyridineethanamine 20218-55-7
      21754-55-2, L-Norleucine methyl ester 22013-33-8, 3,4-
      Ethylenedioxyaniline 22374-89-6 23095-31-0, 3,4-
      Dimethoxybenzenesulfonyl chloride 23583-21-3, N-Benzyl-3-aminopropionic
      acid ethyl ester 24313-88-0, 3,4, 5-Trimethoxyaniline 26348-61-8,
      L-Serine ethyl ester hydrochloride 27757-85-3, 2-(Aminomethyl)thiophene
      28292-43-5, 1,4-Dimethylpentylamine 29289-13-2, 2-Iodo-4-Methyl-aniline
      29602-39-9, 2-(2-Aminoethylamino)-5-nitro-pyridine 32923-88-9,
      3-Isobutoxypropylamine 32953-14-3, N-Ethyl-3,4 (methylenedioxy)aniline
     34698-41-4, 1-Aminoindane 35303-76-5 39811-17-1 39895-55-1,
      4-Tert-Butylbenzylamine 42882-31-5, 1-(1-Naphthyl)ethylamine
      43064-12-6, 4-Phenyl-1,2,3,6-tetrahydropyridine hydrochloride
                 51600-24-9 52516-13-9, 2,4-Dichloro phenethylamine
      50823-90-0
                52605-49-9, Sarcosine ethyl ester hydrochloride
                                                                  55456-40-1
      52516-30-0
      55536-65-7, 3,4-Dibenzyloxy phenethylamine 55674-63-0,
                                                        58632-95-4, Boc-ON
     N-(tert-Butoxycarbonyl)-D-norleucine 55881-33-9
      58859-46-4, Ethyl 4-amino-1-piperidinecarboxylate
                                                        61296-22-8
      66270-97-1, 4-(Bromomethyl) phenyl acetic acid phenacyl ester
      71773-95-0, L-Alanine ethylamide 73918-56-6, 4-Bromo phenethylamine
      79069-13-9, N-(tert-Butoxycarbonyl)-L-alaninol
                                                     85068-29-7 85642-13-3
      88116-02-3, 1-Bromomethyl-2-[(phenylsulfonyl)methyl]benzene 89499-43-4,
      Methyl 3-aminothiophene-4-carboxylate 90390-15-1 93071-75-1
      93919-56-3 102830-49-9 108329-74-4 118468-18-1
                                                           127095-92-5,
     N-(tert-Butoxycarbonyl)-D-cyclohexylalanine 228401-14-7
                                                                248931-34-2
        (prepn. of substituted .beta.-amino acid as inhibitors of methionine
       aminopeptidase and angiogenesis)
     ANSWER 11 OF 18 USPATFULL
L2
      1998:160057 USPATFULL
AN
      Modification of porous and non-porous materials using self-assembled
TI
      monolayers
      Belfort, Georges, Slingerlands, NY, United States
IN
      Boehme, Peter, Troy, NY, United States
      Rensselner Polytechnic Institute, Troy, NY, United States (U.S.
PA
      corporation)
                              19981222
PI
      US 5852127
      US 1996-680529
                              19960709 (8)
AΙ
DT
      Utility
FS
      Granted
      Primary Examiner: Michl, Paul R.
EXNAM
      Notaro & Michalos, PC
LREP
      Number of Claims: 8
CLMN
ECL
      Exemplary Claim: 1
      9 Drawing Figure(s); 5 Drawing Page(s)
DRWN
LN.CNT 476
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
      75-39-8, 1-Aminoethanol 10121-91-2, Dansyl cadaverine
      27072-45-3, FITC
        (modification of porous and nonporous polymer materials using
       self-assembled monolayers for immobilization of)
```

```
ANSWER 12 OF 18 USPATFULL
L2
       1998:154446 USPATFULL
AN
       Thiadiazole derivatives useful for the treatment of diseases related to
TI
       connective tissue degradation
       Jacobsen, Eric J., Plainwell, MI, United States
IN
       Mitchell, Mark A., Kalamazoo, MI, United States
       Schostarez, Heinrich J., Portage, MI, United States
       Harper, Donald E., Plainwell, MI, United States
       Pharmacia & Upjohn Company, Kalamazoo, MI, United States (U.S.
PA
       corporation)
                               19981208
       US 5847148
PΙ
                               19970410 (8)
       US 1997-835599
ΑI
                           19960423 (60)
       US 1996-16003P
PRAI
       Utility
DТ
FS
       Granted
EXNAM Primary Examiner: Richter, Johann; Assistant Examiner: Keating, Dominic
       Yang, Lucy X.
LREP
       Number of Claims: 15
CLMN
       Exemplary Claim: 1
ECL
DRWN
       No Drawings
LN.CNT 2161
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
      64-04-0, Phenethylamine
                                92-54-6, 1-Phenylpiperazine
                                                              118-31-0,
TT
      1-Naphthalenemethylamine
                               123-90-0, Thiomorpholine
                                                            124-40-3,
      Dimethylamine, reactions 156-87-6, 3-Amino-1-propanol
                                                                841-77-0,
                             1943-82-4, Phenethyl isocyanate
      1-Benzhydrylpiperazine
                                                                2038-03-1,
                               2038-57-5, 3-Phenylpropylamine
                                                                2349-67-9,
      4-Morpholineethanamine
      1,3,4-Thiadiazole-2(3H)-thione, 5-amino-
                                               2620-50-0, Piperonylamine
                2759-28-6, Benzylpiperazine
                                              3173-56-6, Benzyl isocyanate
      2717-76-2
      3218-02-8, Cyclohexanemethanamine
                                         3300-51-4, 4-
                                   3731-51-9, 2-(Aminomethyl)pyridine
      (Trifluoromethyl) benzylamine
      3731-52-0, 3-(Aminomethyl)pyridine
                                          3731-53-1, 4-(Aminomethyl)pyridine
      4244-84-2, .beta.-Alanine ethyl ester hydrochloride
                                                            5763-61-1,
      Veratrylamine 5805-57-2, 2-(Aminomethyl)benzimidazole
                                                                7409-30-5,
                          7524-50-7, L-Phenylalanine methyl ester
      4-Nitrobenzylamine
      hydrochloride 10121-91-2, Monodansylcadaverine
                                                      13033-84-6.
      D-Phenylalanine methyl ester hydrochloride
                                                 13214-66-9,
      4-Phenylbutylamine 15028-39-4 16741-80-3 17114-97-5
                  19525-87-2
                               20980-22-7, 1-(2-Pyrimidinyl)piperazine
      17355-19-0
      34803-66-2, 1-(2-Pyridyl)piperazine 38212-30-5, 1-(4-
      Methoxyphenyl)piperazine 39895-55-1, 4-tert-Butylbenzylamine
      57260-71-6
                 71449-22-4
                                71989-43-0 88576-93-6 95260-87-0
      98642-61-6, o-(tert-Butyldimethylsilyl)-L-serine methyl ester
                                                163210-86-4
                    139040-51-0
                                 149193-77-1
                                                              198701-47-2
      112306-76-0
                                  198701-50-7
      198701-48-3
                    198701-49-4
                                                198701-51-8
                                                              198701-52-9
                    198701-54-1
                                  216974-09-3
      198701-53-0
        (prepn. of thiadiazole amino acid derivs. for treatment of diseases
        related to connective tissue degrdn.)
     ANSWER 13 OF 18 USPATFULL
L2
       96:92090 USPATFULL
AN
TI
       Macrocyclic amide and urea immunomodulators
       Wagner, Rolf, Libertyville, IL, United States
IN
       Luly, Jay R., Libertyville, IL, United States
       Or, Yat S., Libertyville, IL, United States
       Abbott Laboratories, Abbott Park, IL, United States (U.S. corporation)
PΑ
PΙ
       US 5563172
                               19961008
AΙ
       US 1994-213394
                               19940314 (8)
       Continuation-in-part of Ser. No. US 1993-149419, filed on 9 Nov 1993,
RLI
       now abandoned which is a continuation-in-part of Ser. No. US 1993-32958,
       filed on 17 Mar 1993, now abandoned which is a continuation-in-part of
       Ser. No. US 1991-755208, filed on 5 Sep 1991, now abandoned
DT
       Utility
FS
       Granted
```

```
EXNAM Primary Examiner: Bond, Robert T.
      Danckers, Andreas M., Crowley, Steven R.
LREP
      Number of Claims: 10
CLMN
ECL
       Exemplary Claim: 1
      No Drawings
DRWN
LN.CNT 5666
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
      54-85-3, Isonicotinic acid hydrazide
                                           62-53-3, Aniline, reactions
      64-04-0, Phenethylamine 79-04-9, Chloroacetyl chloride
      3,4-Dichloroaniline 98-16-8, 3-(Trifluoromethyl)aniline
      Benzylamine, reactions 103-67-3, N-Methylbenzylamine
                                                              104-94-9,
      4-Methoxyaniline 106-47-8, 4-Chloroaniline, reactions
                             108-00-9, 2-(Dimethylamino)ethylamine
      p-Toluidine, reactions
      108-91-8, Cyclohexylamine, reactions 109-01-3, N-Methylpiperazine
      109-55-7, 3-(Dimethylamino) propylamine 109-83-1, 2-(Methylamino) ethanol
      110-89-4, Piperidine, reactions 110-91-8, Morpholine, reactions
                                                        123-00-2,
      111-42-2, N,N-Bis(2-hydroxyethyl)amine, reactions
      [3-(Morpholino)propyl]amine 123-30-8, p-Aminophenol
                     141-43-5, 2-Aminoethanol, reactions
      Thiomorpholine
     Aziridine, reactions 156-57-0, 2-Aminoethanethiol hydrochloride
      156-87-6, 3-Aminopropan-1-ol 177-11-7, 1,4-Dioxa-8-azaspiro[4.5]decane
      371-40-4, 4-Fluoroaniline 372-19-0, m-Fluoroaniline 455-14-1,
      4-Aminobenzotrifluoride 462-08-8, 3-Aminopyridine 504-24-5,
      4-Aminopyridine 504-29-0, 2-Aminopyridine 534-03-2, Serinol
      591-27-5 619-73-8, 4-Nitrobenzyl alcohol 623-48-3, Ethyl iodoacetate
      623-73-4, Ethyl diazoacetate 626-01-7, 3-Iodoaniline
                                                             628-87-5,
      Iminodiacetonitrile 962-39-0, L-Phenylalanine benzyl ester
     N, N-Dimethylphenethylamine 1583-88-6, [2-(4-Fluorophenyl)ethyl]amine
                 1738-68-7, Glycine benzyl ester 2038-03-1,
      1656-94-6
      [2-(Morpholino)ethyl]amine 2524-67-6, 4-Morpholinoaniline
                                                                   3913-67-5,
     N-Methylalanine 4319-49-7, 4-Aminomorpholine
                                                      4543-96-8
      10121-91-2, Dansylcadaverine 13325-10-5, 4-Aminobutan-1-ol
      14529-00-1, .beta.-Alanine benzyl ester 31121-11-6
                                                           35836-73-8,
      (-)-Nopol 39093-93-1, Thiomorpholine dioxide
                                                     52267-51-3, Benzyl
      diazoacetate 81867-37-0, Benzyl iodoacetate
                                                     104987-12-4, Ascomycin
      160843-76-5, 9-Fluorenylmethyl diazoacetate
        (prepn. of macrocyclic amide and urea immunomodulators)
    ANSWER 14 OF 18 USPATFULL
L2
       93:20396 USPATFULL
AN
      Methods of making fluorescent microspheres
ΤI
       Cheung, Sau W., 8528 Douglas Ct., St. Louis, MO, United States 63144
IN
      US 5194300
                              19930316
PΙ
      US 1989-433677
                              19891108 (7)
ΑI
      Division of Ser. No. US 1987-73770, filed on 15 Jul 1987, now abandoned
RLI
DT
      Utility
FS
       Granted
EXNAM Primary Examiner: Stoll, Robert L.; Assistant Examiner: Covert, John M.
      Polster, Lieder, Woodruff & Lucchesi
LREP
      Number of Claims: 20
CLMN
      Exemplary Claim: 1
ECL
       1 Drawing Figure(s); 1 Drawing Page(s)
LN.CNT 584
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 10121-91-2, Dansylcadaverine
        (polyacrylate microspheres labeled with, for biochem. anal. by specific
       binding assay and fluorescence microscopy)
L2
    ANSWER 15 OF 18 USPATFULL
AN
      92:59815 USPATFULL
      Fluorescent microspheres and methods of using them
ΤI
       Cheung, Sau W., 8528 Douglas Ct., St. Louis, MO, United States 63144
IN
PT.
      US 5132242
                              19920721
ΑI
      US 1989-434892
                              19891113 (7)
```

```
Continuation-in-part of Ser. No. US 1987-73770, filed on 15 Jul 1987,
RLI
       now abandoned
       Utility
DT
       Granted
FS
EXNAM Primary Examiner: Ceperley, Mary E.
       Polster, Lieder, Woodruff and Lucchesi
LREP
       Number of Claims: 15
CLMN
       Exemplary Claim: 1
ECL
       1 Drawing Figure(s); 1 Drawing Page(s)
DRWN
LN.CNT 625
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 10121-91-2, Dansylcadaverine
        (polyacrylate microspheres labeled with, for biochem. anal. by specific
        binding assay and fluorescence microscopy)
     ANSWER 16 OF 18 USPATFULL
T<sub>1</sub>2
       92:51100 USPATFULL
ΔN
ΤI
       Effect of transglutaminase inhibition on microfilariae development and
       macrofilariae viability
TN
       Kapil, Mehta, Houston, TX, United States
       Rao, Undaru R., Tampa, FL, United States
       Vickery, Ann C., Tampa, FL, United States
       The Board of Reagents The University of Texas System, Austin, TX, United
PA
       States (U.S. corporation)
       US 5124358
                               19920623
PT
       US 1990-466127
                               19900116 (7)
ΑI
       Utility
DT
       Granted
FS
EXNAM Primary Examiner: Robinson, Allen J.
       Arnold, White and Durkee
LREP
       Number of Claims: 18
CLMN
       Exemplary Claim: 1
ECL
       11 Drawing Figure(s); 3 Drawing Page(s)
DRWN
LN.CNT 983
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
      51-45-6, Histamine, biological studies
                                                51-85-4, Cystamine 74-89-5,
      Methylamine, biological studies 110-60-1, Putrescine 144-48-9,
      Iodoacetamide 504-73-4D, 3,5-substituted derivs. 768-94-5,
      Tricyclo[3.3.1.13,7]decan-1-amine 10121-91-2, Dansyl cadaverine
                 138214-74-1
      13392-28-4
        (as transglutaminase inhibitor for filaricide)
     ANSWER 17 OF 18 USPATFULL
L2
AN
       86:41095 USPATFULL
TΤ
       Method for measuring the activity of plasma factor XIII
       Ogawa, Kazuo, Chiba, Japan
TN
       Baba, Setsuko, Chiba, Japan
       Nakanishi, Kazuo, Yokohama, Japan
       Iatron Laboratories, Inc., Tokyo, Japan (non-U.S. corporation)
PA
PΤ
       US 4601977
                               19860722
       US 1983-502473
                               19830609 (6)
AΙ
       JP 1982-99284
PRAI
                           19820611
DТ
       Utility
FS
       Granted
EXNAM Primary Examiner: Rosen, Sam
       Jeffers, Albert L., Belsheim, Stephen T.
LREP
CLMN
       Number of Claims: 2
ECL
       Exemplary Claim: 1
DRWN
       3 Drawing Figure(s); 3 Drawing Page(s)
LN.CNT 204
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
      462-94-2D, derivs. 10121-91-2
        (blood coagulation factor XIII detn. in human plasma with)
```

```
ANSWER 18 OF 18 USPATFULL
L2
       83:32930 USPATFULL
AN
       Antiviral activities of dansylcadaverine and closely related compounds
ΤI
       Pastan, Ira H., Potomac, MD, United States
IN
       Willingham, Mark C., Bethesda, MD, United States
       The United States of America as represented by the Department of Health
PA
       & Human Services, Washington, DC, United States (U.S. government)
       US 4396628
                               19830802
PΙ
ΑI
       US 1982-352599
                               19820226 (6)
       Continuation-in-part of Ser. No. US 1981-275033, filed on 18 Jun 1981,
RLI
       now abandoned
       Utility
DT
FS
       Granted
EXNAM Primary Examiner: Goldberg, Jerome D.
      Roberts, Jr., John S.
LREP
       Number of Claims: 3
CLMN
       Exemplary Claim: 1
ECL
       5 Drawing Figure(s); 5 Drawing Page(s)
DRWN
LN.CNT 259
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 10121-91-2
       (virucide)
IT 10121-91-2D, analogs
        (virucides)
```

=>